This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Primary objectives This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage F2 or F3 and consists of 2 sequential parts - an initial double-blind placebo-controlled (DBPC) period (Part A) followed by a double-blind active treatment extension (ATE) period (Part B), with the following primary objectives: Part A To assess the safety and efficacy of lanifibranor compared to placebo on 'NASH resolution and improvement of fibrosis' assessed by liver histology. Part B To assess the safety of lanifibranor beyond the DBPC period. Secondary objectives Key secondary objectives of Part 1: * To assess the effect of lanifibranor compared to placebo on NASH resolution and no worsening of fibrosis * To assess the effect of lanifibranor compared to placebo on improvement of fibrosis with no worsening of NASH Other secondary objectives of both Part 1 and Part 2: * To assess the effect of lanifibranor on other key histological features of NASH (only for DBPC period) * To assess the effect of lanifibranor on NASH resolution and improvement of fibrosis in diabetic patients (only for DBPC period) * To assess the effect of lanifibranor on liver tests * To assess the effect of lanifibranor on glycaemic parameters * To assess the effect of lanifibranor on lipid parameters * To assess the effect of lanifibranor on liver stiffness and steatosis assessed by elastography. * To assess the effect of lanifibranor on health-related quality of life * To assess the safety of lanifibranor * To assess population PK modeling through plasma levels of lanifibranor using sparse sampling scheme (only for DBPC period)